US · VRAX
Virax Biolabs Group Limited
- Sector
- Healthcare · Biotechnology
- Headquarters
- London W1F 8LX
- Website
- viraxbiolabs.com
Price · as of 2025-03-31
$0.13
Market cap 988.66K
Valuation summary
Four models, one snapshot. Upside is target ÷ current − 1.
| Valuation method | Value, $ | Upside, % |
|---|---|---|
| Artificial Intelligence(AI) | $134.34 | +101,827.16% |
| Intrinsic Value(DCF) | $0.39 | +195.9% |
| Graham-Dodd Method(GD) | — | — |
| Graham Formula(GF) | $163.80 | +124,177.69% |
Valuation history
Annual price (USD per share) overlaid with each model's fair value. Y-axis is log scale.
| Year | Price | AI | DCF | Graham-Dodd | Graham Formula |
|---|---|---|---|---|---|
| 2011 | |||||
| 2012 | |||||
| 2013 | |||||
| 2014 | |||||
| 2015 | |||||
| 2016 | |||||
| 2017 | |||||
| 2018 | |||||
| 2019 | |||||
| 2020 | |||||
| 2021 | $0.00 | $0.00 | |||
| 2022 | |||||
| 2023 | $4.25 | $2.74 | $0.00 | ||
| 2024 | $1.97 | $205.78 | $2,159.97 | $0.00 | $0.00 |
| 2025 | $0.98 | $134.34 | $0.00 | $0.00 | $163.80 |
AI valuation
Our deep-learning model estimates Virax Biolabs Group Limited's (VRAX) per-share fair value from quarterly fundamentals, sector trend, and historical valuation patterns.
- AI fair value
- $134.34
- Current price
- $0.13
- AI upside
- +101,827.16%
Methodology and confidence bands appear in the dedicated valuation theory section. The AI score is an estimate, not a recommendation.
Intrinsic value (DCF)
Open DCF calculatorThree textbook valuation models, recomputed daily from the latest financial statements. The DCF uses our Chepakovich model. Graham-Dodd and Graham Formula are conservative reference points.
DCF
$0.39
+195.9% upside
Graham-Dodd
—
— upside
Graham Formula
$163.80
+124,177.69% upside
Peer comparison
Same-industry comparables, ranked by market cap.
| Basic Info | Model Valuation | Core Valuation | Profitability | Leverage & Liquidity | Growth | Cash Flow | Dividends | Enterprise Value | Risk | ||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ticker | Company Name | Price | Market Cap | AI Upside | DCF Upside | GD Upside | GF Upside | P/E | P/B | P/S | EV/EBITDA | PEG | P/TBV | Gross Margin | Operating Margin | Net Margin | ROE | ROIC | ROA | Debt/Equity | Interest Coverage | Current Ratio | Quick Ratio | Net Debt/EBITDA | EPS Growth | Sales Growth | FCF Growth | FCF Yield | Op Cash Flow Ratio | Cash ROIC | Dividend Yield | Dividend Payout | Shareholder Yield | EV/EBIT | EV/FCF | EV/Sales | Altman Z-Score |
| VRAX | Virax Biolabs Group Limit… | $0.13 | 988.66K | +101,827% | +196% | — | +124,178% | -0.50 | 0.53 | 478.92 | 0.14 | — | 0.54 | -838.21% | -97344.76% | -95739.17% | -109.69% | -313.42% | -101.88% | 0.07 | -105.93 | 7.27 | 6.33 | 0.66 | -4196.00% | -9595.00% | -3028.00% | -170.43% | -6.78 | -268.72% | 0.00% | 0.00% | 16.06% | 0.13 | 0.16 | -129.50 | -5.85 |
| ARTL | Artelo Biosciences, Inc. | $1.19 | 2.75M | — | — | — | — | -0.09 | -0.92 | — | -0.10 | -0.03 | -0.35 | 0.00% | — | — | -1625.11% | 4102.16% | -343.49% | -0.54 | -58.78 | 0.17 | 0.15 | -0.01 | 31049.00% | — | 204.00% | -726.31% | -2.11 | 3064.75% | 0.00% | 0.00% | 0.00% | -0.11 | -0.15 | — | -46.19 |
| DRMA | Dermata Therapeutics, Inc… | $1.20 | 817.87K | — | — | — | — | -0.15 | 1.19 | — | 0.11 | — | 1.19 | 0.00% | — | — | -310.44% | 932.57% | -213.46% | 0.00 | — | 1.79 | 1.60 | 0.26 | -7991.00% | — | 7418.00% | -602.98% | -5.66 | 831.94% | 0.00% | 0.00% | 0.04% | 0.10 | 0.12 | — | -36.61 |
| ELAB | PMGC Holdings Inc. | $1.19 | 126.21K | +401,467% | +24,631% | — | — | -0.06 | 0.06 | 0.16 | 1.12 | — | 0.10 | 72.84% | -75.65% | -253.14% | -119.12% | -110.26% | -88.07% | 0.00 | -2.54 | 3.36 | 2.22 | 1.25 | -8600.00% | 4407.00% | 2032.00% | -1366.73% | -3.05 | -324.66% | 0.00% | 0.00% | 215.87% | 1.92 | 0.65 | -1.45 | -1.81 |
| GTBP | GT Biopharma, Inc. | $0.48 | 5.08M | — | — | — | — | -0.35 | -2.77 | — | -0.05 | -1.53 | -2.77 | 0.00% | — | — | -453.39% | 238.23% | -143.53% | 0.00 | — | 0.72 | 0.67 | 0.30 | 2305.00% | — | 4577.00% | -278.78% | -2.19 | 214.01% | 0.00% | 0.00% | 63.30% | -0.05 | -0.05 | — | -241.19 |
| MLEC | Moolec Science S.A. | $13.30 | 9.66M | +7,515% | +24,189,467% | — | — | -0.07 | -0.12 | 0.02 | -3.56 | 0.00 | -0.05 | 34.17% | -3.14% | -33.41% | 376.84% | -11.15% | -93.08% | -3.74 | -0.25 | 0.13 | 0.12 | -3.57 | 897895.00% | 583074.00% | 21733.00% | -393.07% | -0.10 | -32.03% | 0.00% | 0.00% | 12.10% | -23.43 | -8.16 | 0.74 | -0.48 |
| NCEL | NewcelX Ltd. | $2.90 | 1.31M | — | — | — | — | -0.65 | 0.91 | — | 0.11 | -0.09 | 0.91 | 0.00% | — | — | 53.34% | 104.83% | -97.10% | 0.00 | -29.20 | 2.69 | 2.50 | 0.46 | 72188.00% | — | -5589.00% | -333.71% | -5.16 | 102.24% | 0.00% | 0.00% | 187.60% | 0.09 | 0.09 | — | -51.45 |
| XRTX | XORTX Therapeutics Inc. | $0.41 | 1.55M | — | — | — | — | -0.75 | 0.97 | — | -0.37 | — | 1.07 | 0.00% | — | — | -119.80% | -346.54% | -95.46% | 0.02 | — | 1.61 | 1.58 | 0.26 | -5273.00% | — | 398.00% | -139.13% | -4.71 | -294.67% | 0.00% | 0.00% | 0.00% | -0.36 | -0.43 | — | -14.31 |
About Virax Biolabs Group Limited
Virax Biolabs Group Limited, a biotechnology company, sells, distributes, and markets diagnostics test kits, and med-tech and PPE products for the prevention, detection, diagnosis, and risk management of viral diseases in the field of immunology. The company provides rapid antibody IgC/IgM tests, antigen tests, polymerase chain reaction rapid tests, and neutralizing antibody tests under the ViraxClear brand name; and med-tech and PPE products, such as employee protection equipment products under the ViraxCare brand name, as well as infrared thermometers, pulse oximeters, masks, gloves, and other PPE products. It also distributes nebulizing machines and smart wearable devices that alert employees to help them follow social distance guidelines. In addition, the company operates an online platform that sells ViraxClear and ViraxCare products. It serves clinics, pharmacies, laboratories, hospitals, and other groups, as well as corporations, employees, individual consumers, hospital systems, and public and private institutions. The company operates in Europe, South America, the Asia Pacific, Sub-Saharan Africa, and internationally. The company was formerly known as Virax Biolabs (Cayman) Limited and changed its name to Virax Biolabs Group Limited in September 2021. Virax Biolabs Group Limited was incorporated in 2021 and is headquartered in London, the United Kingdom.
- CEO
- James Foster
- Employees
- 17
- Beta
- 1.67
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Upside computed as ($0.39 ÷ $0.13) − 1 = +195.9% (DCF, example).